{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:37:59Z","timestamp":1794310679212,"version":"4.9.0"},"reference-count":115,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.anai.2023.05.016","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T20:51:15Z","timestamp":1684788675000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Aspirin-exacerbated respiratory disease"],"prefix":"10.1016","volume":"131","author":[{"given":"Jyotsna","family":"Mullur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Buchheit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.anai.2023.05.016_bib0001","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0002","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0004","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.wjorl.2020.07.003","article-title":"The importance of timely diagnosis of aspirin-exacerbated respiratory disease for patient health and safety","volume":"6","author":"Buchheit","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0006","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaip.2016.05.016","article-title":"Aspirin-exacerbated respiratory disease: not always \u201cadult-onset\u201d","volume":"4","author":"Tuttle","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"10.1016\/j.anai.2023.05.016_bib0007","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.jaip.2022.05.016","article-title":"Pediatric-onset aspirin-exacerbated respiratory disease: clinical characteristics, prevalence, and response to dupilumab","volume":"10","author":"Bensko","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0008","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/lary.23610","article-title":"Role of frontal sinus surgery in nasal polyp recurrence","volume":"123","author":"Bassiouni","year":"2013","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2500\/ajr.2006.20.2913","article-title":"Medical and surgical considerations in patients with Samter's triad","volume":"20","author":"McMains","year":"2006","journal-title":"Am J Rhinol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0010","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaip.2018.10.032","article-title":"A 1-day, 90-minute Aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease","volume":"7","author":"DeGregorio","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0011","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaip.2018.08.004","article-title":"Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease","volume":"7","author":"Pelletier","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0012","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D2: a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0013","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jaci.2012.04.016","article-title":"Aspirin as a cause of pancreatitis in patients with aspirin-exacerbated respiratory disease","volume":"129","author":"Stevenson","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0014","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cea.12836","article-title":"Alcohol hyper-responsiveness in chronic rhinosinusitis with nasal polyps","volume":"47","author":"De Schryver","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaip.2013.12.003","article-title":"Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease","volume":"2","author":"Cardet","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0016","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4168\/aair.2015.7.4.312","article-title":"Seven steps to the diagnosis of NSAIDs hypersensitivity: how to apply a new classification in real practice?","volume":"7","author":"Kowalski","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0017","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jaip.2018.12.014","article-title":"Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease","volume":"7","author":"Jerschow","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0018","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2019.02.037","article-title":"Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD","volume":"7","author":"Huang","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-018-0909-6","article-title":"The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease","volume":"19","author":"Comhair","year":"2018","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2023.05.016_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.734733","article-title":"Pathomechanisms of AERD-recent advances","volume":"2","author":"Lyly","year":"2021","journal-title":"Front Allergy"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0022","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaci.2021.06.016","article-title":"Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease","volume":"148","author":"Eid","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2021.02.045","article-title":"Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis","volume":"148","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"56","key":"10.1016\/j.anai.2023.05.016_bib0024","doi-asserted-by":"crossref","first-page":"eabb7221","DOI":"10.1126\/sciimmunol.abb7221","article-title":"Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation","volume":"6","author":"Dwyer","year":"2021","journal-title":"Sci Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0025","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaci.2013.12.1092","article-title":"Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity","volume":"133","author":"Mahdavinia","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0026","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1164\/ajrccm.153.1.8542168","article-title":"Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects","volume":"153","author":"Nasser","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.anai.2020.09.016","article-title":"Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease","volume":"126","author":"Buchheit","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0028","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jaci.2020.02.035","article-title":"IL-5R\u03b1 marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease","volume":"145","author":"Buchheit","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"10.1016\/j.anai.2023.05.016_bib0029","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","article-title":"Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes","volume":"119","author":"Laidlaw","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.201002-0295OC","article-title":"Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program","volume":"183","author":"Balzar","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0031","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaci.2005.02.022","article-title":"Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell","volume":"115","author":"Oskeritzian","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0032","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.anai.2020.09.011","article-title":"Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease","volume":"126","author":"Cavagnero","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0033","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jaci.2015.10.020","article-title":"Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease","volume":"137","author":"Buchheit","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0034","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2018.06.033","article-title":"COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: implications for aspirin sensitivity","volume":"143","author":"Pan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.anai.2023.05.016_bib0035","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.4049\/jimmunol.1500905","article-title":"Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway","volume":"195","author":"Liu","year":"2015","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0036","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jaci.2004.07.013","article-title":"Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis","volume":"114","author":"Van Zele","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0037","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2020.11.001","article-title":"Inflammatory heterogeneity in aspirin-exacerbated respiratory disease","volume":"147","author":"Scott","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0038","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jaip.2022.03.021","article-title":"Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease","volume":"10","author":"Corey","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4, pt 1","key":"10.1016\/j.anai.2023.05.016_bib0039","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1164\/ajrccm.149.4.8143059","article-title":"Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge","volume":"149","author":"Sladek","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1067\/mai.2003.1387","article-title":"A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge","volume":"111","author":"Bochenek","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0041","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2332\/allergolint.O-08-545","article-title":"Correlation between the prostaglandin D(2)\/E(2) ratio in nasal polyps and the recalcitrant pathophysiology of chronic rhinosinusitis associated with bronchial asthma","volume":"57","author":"Yoshimura","year":"2008","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0042","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease\u2013new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N Engl J Med"},{"issue":"5, pt 1","key":"10.1016\/j.anai.2023.05.016_bib0043","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/ajrccm\/143.5_Pt_1.1025","article-title":"Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects","volume":"143","author":"Christie","year":"1991","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0044","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/thx.2007.080903","article-title":"Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity","volume":"63","author":"Mastalerz","year":"2008","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0045","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/ajrccm.153.2.8564100","article-title":"Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma","volume":"153","author":"Sestini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0046","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0047","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0091-6749(80)90143-8","article-title":"Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges","volume":"66","author":"Stevenson","year":"1980","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0048","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaci.2006.09.011","article-title":"Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease","volume":"119","author":"Lee","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0049","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","volume":"147","author":"Stevens","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0050","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.201809-1755OC","article-title":"Unique effect of aspirin therapy on biomarkers in aspirin-exacerbated respiratory disease. A prospective trial","volume":"200","author":"Cahill","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0051","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1164\/rccm.201904-0716ED","article-title":"Aspirin-exacerbated respiratory disease: A syndrome of mast cell-mediated PgD2 overproduction","volume":"200","author":"Borish","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0052","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"\u015awierczy\u0144ska-Krepa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0053","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0091-6749(96)70123-9","article-title":"Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes","volume":"98","author":"Stevenson","year":"1996","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0054","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1067\/mai.2003.7","article-title":"Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"111","author":"Berges-Gimeno","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/all.12131","article-title":"Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease","volume":"68","author":"Fruth","year":"2013","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.anai.2023.05.016_bib0056","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","article-title":"Lower use of biologics for the treatment of asthma in publicly insured individuals","volume":"9","author":"Akenroye","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0057","first-page":"1639","article-title":"Clinical and immunological efficacy of aspirin desensitization in nasal polyp patients with aspirin-exacerbated respiratory disease","volume":"16","author":"Mortazavi","year":"2017","journal-title":"Iran J Pharm Res"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0058","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clim.2015.05.012","article-title":"Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial","volume":"160","author":"Esmaeilzadeh","year":"2015","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0059","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0091-6749(62)80451-5","article-title":"Aspirin in chronic urticaria and\/or angioedema: studies of sensitivity and desensitization","volume":"69","author":"Mathison","year":"1982","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0061","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2016.06.016","article-title":"A survey of aspirin desensitization practices among allergists and fellows in training in the United States","volume":"4","author":"Waldram","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0062","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.anai.2022.03.012","article-title":"If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?","volume":"128","author":"White","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0063","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.wjorl.2020.07.009","article-title":"Aspirin-exacerbated respiratory disease: update on medical management","volume":"6","author":"White","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"12","key":"10.1016\/j.anai.2023.05.016_bib0064","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0065","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jaip.2016.11.021","article-title":"Plasma 15-hydroxyeicosatetraenoic acid predicts treatment outcomes in aspirin-exacerbated respiratory disease","volume":"5","author":"Jerschow","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"16","key":"10.1016\/j.anai.2023.05.016_bib0066","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.2022.3337","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"327","author":"Guirguis-Blake","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.anai.2023.05.016_bib0067","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/alr.21826","article-title":"Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations","volume":"6","author":"Levy","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"issue":"12","key":"10.1016\/j.anai.2023.05.016_bib0068","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/alr.22418","article-title":"Endoscopic sinus surgery improves aspirin treatment response in aspirin-exacerbated respiratory disease patients","volume":"9","author":"Shah","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0069","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1081-1206(10)61150-7","article-title":"The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease","volume":"95","author":"White","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.05.016_bib0070","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1046\/j.1365-2745.2002.01501.x","article-title":"The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions","volume":"32","author":"Berges-Gimeno","year":"2002","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0071","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4168\/aair.2010.2.1.48","article-title":"Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics","volume":"2","author":"Park","year":"2010","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0072","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jaip.2020.10.041","article-title":"Effect of LTRA in L-ASA Challenge for aspirin-exacerbated respiratory disease diagnosis","volume":"9","author":"Ram\u00edrez-Jim\u00e9nez","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0073","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahl\u00e9n","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0074","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1398-9995.2003.00351.x","article-title":"Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo","volume":"59","author":"Micheletto","year":"2004","journal-title":"Allergy"},{"issue":"4, pt 1","key":"10.1016\/j.anai.2023.05.016_bib0075","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1164\/ajrccm.157.4.9707089","article-title":"Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics","volume":"157","author":"Dahl\u00e9n","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0076","doi-asserted-by":"crossref","first-page":"AB384","DOI":"10.1016\/j.jaci.2016.12.924","article-title":"Efficacy of zileuton in patients with asthma and history of aspirin sensitivity: a retrospective analysis of data from two Phase 3 studies","volume":"139","author":"Laidlaw","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0077","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/1945892419873211","article-title":"Effect of zileuton treatment on sinonasal quality of life in patients with aspirin-exacerbated respiratory disease","volume":"33","author":"Lee","year":"2019","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2021.103227","article-title":"Long-term role of zileuton in the treatment of chronic rhinosinusitis in aspirin exacerbated respiratory disease","volume":"43","author":"Makary","year":"2022","journal-title":"Am J Otolaryngol"},{"issue":"12","key":"10.1016\/j.anai.2023.05.016_bib0079","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1164\/rccm.202003-0783ED","article-title":"Does IgE have a role in aspirin-exacerbated respiratory disease?","volume":"201","author":"Busse","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.anai.2023.05.016_bib0080","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.jaip.2022.06.016","article-title":"The role of omalizumab in NSAID-exacerbated respiratory disease: A narrative review","volume":"10","author":"Taniguchi","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0081","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2500\/ajra.2014.28.4054","article-title":"Elevated total serum IgE in nonatopic patients with aspirin-exacerbated respiratory disease","volume":"28","author":"Johns","year":"2014","journal-title":"Am J Rhinol Allergy"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0082","doi-asserted-by":"crossref","first-page":"1585.e4","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0083","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0084","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: A single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.2500\/aap.2019.40.4241","article-title":"Effect of omalizumab on outcomes in patients with aspirin-exacerbated respiratory disease","volume":"40","author":"Jean","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0086","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib122","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"issue":"10","key":"10.1016\/j.anai.2023.05.016_bib120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2023.05.016_bib0090","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0091","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.anai.2023.05.016_bib121","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0098","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2023.05.016_bib0087","unstructured":"Food and Drug Administration. Highlights of prescribing information: NUCALA (mepolizumab). https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF. Accessed March 3, 2023."},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0088","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0089","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0092","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0093","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0094","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-020-01248-x","article-title":"Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study","volume":"20","author":"Numata","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0096","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI5909","article-title":"Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production","volume":"103","author":"Zhu","year":"1999","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0097","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1165\/ajrcmb.16.4.9115759","article-title":"A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion","volume":"16","author":"Temann","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0099","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy"},{"issue":"7","key":"10.1016\/j.anai.2023.05.016_bib0100","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.jaip.2021.02.020","article-title":"Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5R\u03b1 in a real-world setting","volume":"9","author":"Bavaro","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0101","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2021.11.020","article-title":"Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease","volume":"128","author":"Patel","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2023.05.016_bib0102","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.anai.2021.05.005","article-title":"Dupilumab improves alcohol tolerance in aspirin-exacerbated respiratory disease","volume":"127","author":"Arnold","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0103","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0104","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0105","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.05.016_bib0106","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.05.016_bib0107","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease-how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2023.05.016_bib0108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.wjorl.2020.06.002","article-title":"Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: a review of preliminary data, efficacy, and cost","volume":"6","author":"Workman","year":"2020","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0109","article-title":"Elaborate biologic approval process delays care of patients with moderate-to-severe asthma","volume":"2","author":"Sehanobish","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0111","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2023.05.016_bib0112","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2500\/aap.2021.42.210002","article-title":"Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease","volume":"42","author":"Sweis","year":"2021","journal-title":"Allergy Asthma Proc"}],"updated-by":[{"DOI":"10.1016\/j.anai.2024.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623003563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623003563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:31:27Z","timestamp":1761053487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623003563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":115,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1081120623003563"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.05.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin-exacerbated respiratory disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}